| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-07-24 | Seattle Genetics (USA - WA) Genentech, a member of Roche Group (USA - CA - Switzerland) | SGN-LIV1A and atezolizumab | triple-negative breast cancer (TNBC) | clinical research | Cancer - Oncology | Clinical research agreement |
| 2017-07-24 | 4D Molecular Therapeutics (USA - CA) the Foundation Fighting Blindness (USA - MD) | intravitreal gene therapeutics using 4DMT-proprietary AAV vectors. | inherited retinal diseases | collaboration | Rare diseases - Genetic diseases - Ophtalmological diseases | Collaboration agreement |
| 2017-07-21 | Alligator Bioscience (Sweden) Aptevo Therapeutics (USA - WA) | ALG.APV-527 | development | Cancer - Oncology | Development agreement | |
| 2017-07-20 | Roche (Switzerland) Oryzon Genomics (Spain) | inhibitors of Lysine Specific Demethylase-1 (LSD1; KDM1A) including ORY-1001 (RG6016) | acute myeloid leukaemia | research - development - licensing | Cancer - Oncology | Termination of an agreement |
| 2017-07-20 | Recipharm (Sweden) LIDDS (Sweden) | Liproca®Depot | prostate cancer | production - manufacturing | Cancer - Oncology | Production agreement |
| 2017-07-20 | Ablynx (Belgium) Sanofi (France) | Nanobody®-based therapeutics | immune mediated inflammatory diseases | research - licensing | Immunological diseases - Inflammatory diseases | Licensing agreement |
| 2017-07-20 | Emergent BioSolutions (USA - MD) GSK (UK) | raxibacumab | anthrax | product acquisition | Infectious diseases | Product acquisition |
| 2017-07-20 | Auris Medical (Switzerland) Otifex Therapeutics (Australia) | AM-125 (betahistine dihydrochloride) | Meniere's disease and other vestibular disorders | product acquisition | Otorhinolaryngology | Product acquisition |
| 2017-07-19 | GSK (UK) | UK manufacturing network | restructuring | Infectious diseases - Respiratory diseases | Restructuring | |
| 2017-07-19 | Sutro Biopharma (USA - CA) | board of directors | nomination | Infectious diseases | Nomination | |
| 2017-07-19 | Sagetis Biotech (Spain) | member of the scientific advisory board | nomination | Cancer - Oncology - Rare diseases | Nomination | |
| 2017-07-18 | Novimmune (Switzerland) Baxalta (USA - IL) now Shire (UK - USA) | novel bispecific antibodies based on kappa-lambda bispecific antibody technology | hemophilia A | R&D - research | Rare diseases - Genetic diseases - Hematological diseases | Research agreement |
| 2017-07-18 | Daiichi Sankyo (Japan) Zymeworks (Canada) | Azymetric™ and Effector Function Enhancement and Control Technology (EFECT™) platforms | licensing - collaboration | Cancer - Oncology | Milestone | |
| 2017-07-18 | 4SC (Germany) Maruho (Japan) | inhibitor of the Kv1.3 ion channel | licensing | Autoimmune diseases - Dermatological diseases | Licensing agreement | |
| 2017-07-18 | Autolus (UK) | chief operating officer, chief business officer, vice-president | nomination | Cancer - Oncology | Nomination | |
| 2017-07-18 | Audentes Therapeutics (USA - CA) | Vice President Scientific Affairs, Europe | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2017-07-17 | Biogen (USA - MA) Isis Pharmaceuticals , now Ionis Pharmaceuticals (USA - CA) | antisense therapies for neurological diseases | neurological diseases, neuromuscular diseases | development | Neurological diseases - Neuromuscular diseases - Neurodegenerative diseases | Milestone |
| 2017-07-14 | Emergent BioSolutions (USA - MD) Sanofi (France) | ACAM2000® (Smallpox (Vaccinia) Vaccine, Live) business | smallpox | product acquisition | Infectious diseases | Product acquisition |
| 2017-07-13 | Achaogen (USA - CA) | nomination | Infectious diseases | Nomination | ||
| 2017-07-13 | Radius Health (USA - MA) Teijin (Japan) | Eladynos®/Tymlos® (abaloparatide) | osteoporosis | development - licensing | Bone diseases | Licensing agreement |
